Advertisement

Search Results

Advertisement



Your search for Chase Doyle,Chase Doyle matches 525 pages

Showing 1 - 50


breast cancer

Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally

A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...

breast cancer
geriatric oncology

Study Reveals Potential Overtreatment of DCIS in Older Women With Limited Life Expectancy

Ductal carcinoma in situ (DCIS) may often be overtreated in older women with limited life expectancy, according to research presented during the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare...

gynecologic cancers

DUO-E Trial: Results Support New Treatment Options in Endometrial Cancer

New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients with advanced or recurrent endometrial cancer, according to data presented during the Society of...

breast cancer
genomics/genetics

Breast-Conserving Therapy in BRCA-Mutation Carriers: Study Looks at Long-Term Outcomes

Recent research has provided valuable insights into the long-term outcomes of patients with pathogenic BRCA1 and BRCA2 mutations who undergo breast-conserving therapy, according to a study presented at the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The observational study found that...

lung cancer

Glecirasib Shows Efficacy and Safety in KRAS G12C–Mutated NSCLC

Glecirasib monotherapy demonstrated efficacy in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) according to data presented during the ASCO Plenary Series: April 2024 Session (Abstract 468214). Results of the pivotal Chinese phase II study of glecirasib...

head and neck cancer

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium. Results of the phase I/II trial showed an overall response rate of 13% and a...

gynecologic cancers

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer

The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...

gastroesophageal cancer

Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer

The combination of the small molecule inhibitor of VEGFR fruquintinib and the chemotherapy paclitaxel presents a potential new second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to data presented during the ASCO Plenary Series: February...

head and neck cancer

Novel MDM2 Inhibitor for Salivary Gland Cancers

A novel MDM2 inhibitor, APG-115 (alrizomadlin), has demonstrated antitumor activity and good tolerability in patients with progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented by Swiecicki et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium ...

head and neck cancer

Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer

Adding the multikinase inhibitor lenvatinib to the PD-1 inhibitor pembrolizumab as initial therapy for recurrent or metastatic head and neck squamous cell carcinoma improved response rates and progression-free survival but did not lead to an overall survival advantage over pembrolizumab...

gastrointestinal cancer
gastroesophageal cancer

Fruquintinib Plus Paclitaxel as Second-Line Treatment for Gastric or Gastroesophageal Junction Cancer

The combination of fruquintinib and paclitaxel is a potential new second-line treatment for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: February 2024 Session (Abstract 438780). Results of the phase III FRUTIGA...

supportive care
integrative oncology

Expert Point of View: Daniel Curtis McFarland, DO, MS

Invited discussant of the abstracts on the virtual mind-body fitness program and the BRIDGE intervention from the 2023 ASCO Quality Care Symposium, Daniel Curtis McFarland, DO, MS, of Wilmot Cancer Center, University of Rochester Medical Center, New York, said they highlight the unmet need...

supportive care
integrative oncology

Integrated Medicine and Collaborative Care: Innovations in Cancer Treatment and Mental Health Care

Recent studies by multidisciplinary teams at Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital are illuminating novel ways to address health-care challenges faced by patients with cancer. The research, presented at the 2023 ASCO Quality Care Symposium, highlights the...

lymphoma

Expert Point of View: Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, Medical Director of Quality Informatics at Memorial Sloan Kettering Cancer Center, New York, offered his thoughts on the combination of venetoclax and ibrutinib in the treatment of mantle cell lymphoma, as presented at the 2023 American Society of Hematology (ASH)...

lymphoma

SYMPATICO Trial: Ibrutinib Plus Venetoclax Improves Progression-Free Survival in Relapsed Mantle Cell Lymphoma

The combination of ibrutinib and venetoclax has led to an improved progression-free survival rate in patients with relapsed or refractory mantle cell lymphoma (MCL), according to findings presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Interim analysis...

leukemia

Expert Point of View: Paul J. Hampel, MD

Paul J. Hampel, MD, a hematologist/oncologist at Mayo Clinic, Rochester, Minnesota, underscored the complexity of this arm of the adaptive FLAIR trial, which compared measurable residual disease (MRD)-directed ibrutinib plus venetoclax with standard, fixed-duration, FCR (fludarabine,...

leukemia

Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?

A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...

Celebrating Excellence: Matthijs Oudkerk, PhD, MD, MSc, Honored for Contributions to Cancer Prevention and Research

The Prevent Cancer Foundation has honored Matthijs Oudkerk, PhD, MD, MSc, with the prestigious James L. Mulshine, MD, International Leadership Award. Dr. Oudkerk is Professor of Radiology at the University of Groningen and Chief Scientific Officer of the Institute for Diagnostic Accuracy in the...

issues in oncology
lung cancer

Beyond Lung Cancer: Leveraging Machine Learning Techniques to Understand Other Diseases

Although computed tomography (CT) screening has emerged as an essential tool for the early detection of lung diseases, there is still a broad range of potential improvements to be made. According to recent research, understanding the patterns of onset for earlier prediction of disease may be...

lung cancer
skin cancer
cost of care

Undocumented Cost-of-Care Discussions: A Missed Opportunity in Cancer Treatment

A recent study underscored the need for integrating cost-of-care conversations in cancer treatment. Results of the population-based analysis, presented at the 2023 ASCO Quality Care Symposium,1 showed that only about 25% of patients with newly diagnosed advanced non–small cell lung cancer (NSCLC)...

leukemia

ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy

Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged 29 and older have not experienced the same treatment benefits, with survival rates still below...

Expert Point of View: Noemí Reguart, MD, PhD

Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to...

lung cancer

Phase III Trial Shows Novel Four-Drug Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...

Expert Point of View: Elizabeth Smyth, MD

Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...

gastroesophageal cancer
immunotherapy

Novel Antibody-Drug Conjugate Under Study in Treatment of Gastric or Gastroesophageal Junction Cancers

A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may prove to be an effective treatment option for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: November 2023.1 (The ASCO Plenary Series is...

Expert Point of View: Bonny Morris, PhD, RN, MSPH

Invited discussant Bonny Morris, PhD, RN, MSPH, of the American Cancer Society, underscored the use of precision medicine education, literacy, and language-concordant educational tools, as well as effective interventions for food insecurity, to improve cancer health equity in underserved rural...

issues in oncology

Community Program Cuts Treatment Delays in Half for Minority and Low-Income Patients

A program aimed at improving access to high-quality cancer care has significantly increased adherence to cancer treatment among minority and low-income communities, according to data presented at the 2023 ASCO Quality Care Symposium.1 The introduction of the ALCANCE-PLUS program in Monterey County, ...

Expert Point of View: Bonny Morris, PhD, RN, MSPH

Invited discussant Bonny Morris, PhD, RN, MSPH, of the American Cancer Society, underscored the significance of the study’s findings for the veteran community. “There are more than 50,000 veterans diagnosed with cancer each year, with the most common cancers being prostate, lung, and colorectal,”...

supportive care

The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning

A decade-long journey toward improving end-of-life care for patients with advanced cancer has demonstrated positive effects on survival, health-care use, and cost of care, according to data presented at the 2023 ASCO Quality Care Symposium.1 Post hoc analysis of an advance care planning...

hematologic malignancies

Allogeneic Hematopoietic Stem Cell Transplantation for Dendritic Cell Neoplasm Subtype

Allogeneic hematopoietic stem cell transplantation can safely and effectively treat patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially during first remission, according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 4988). Results of the...

hematologic malignancies

Overcoming BPDCN: Tagraxofusp Sets New Landmark in Patient Survival

A novel first-in-class therapy may help to redefine survival expectations for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 547). Results of a European named-patient program study showed...

hematologic malignancies

Age, Race, and Sex Found to Impact Survival Rates in Patients With BPDCN

Age, race, and sex have significant implications for survival rates of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 5185). Findings from the largest U.S. population–based BPDCN study...

issues in oncology
supportive care

Expert Point of View: Kerin B. Adelson, MD, MHCDS

Discussant of these abstracts on the Oncology Care Model (OCM), Kerin B. Adelson, MD, MHCDS, Chief Quality and Value Officer at The University of Texas, MD Anderson Cancer Center, suggested the OCM was beneficial for both patients and health professionals despite the lack of clear positive ...

issues in oncology
supportive care

Oncology Care Model: Studies Find Significant Savings but Minor Quality Improvement

A pair of studies evaluating the impact of the Oncology Care Model (OCM) has highlighted challenges in improving quality of the value-based payment model, according to data presented at the 2023 ASCO Quality Care Symposium. Both studies were conducted by the Centers for Medicare & Medicaid...

leukemia

Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data

Greater understanding of biological disease factors in acute myeloid leukemia (AML) has led to more effective and personalized treatment options. At the 2023 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies,1 Rebecca Olin, MD, MSCE, of UCSF Helen Diller Family...

lung cancer

Expert Point of View: Justin F. Gainor, MD

Discussant of the abstract on the ASTRUM-004 trial, Justin F. Gainor, MD, emphasized the significant, positive improvements in survival among patients randomly assigned to receive the PD-1 inhibitor serplulimab vs placebo. Dr. Gainor is Director of the Center for Thoracic Cancers Program, Director ...

lung cancer

ASTRUM-004: Serplulimab Plus Chemotherapy as First-Line Treatment of Advanced Squamous Non–Small Cell Lung Cancer

A novel treatment approach to squamous non–small cell lung cancer (NSCLC) may improve the prognosis for patients with previously limited treatment options, according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 Findings from ...

Expert Point of View: Lori J. Pierce, MD, FASTRO, FASCO

Despite the lack of long-term follow-up, abstract discussant Lori J. Pierce, MD, FASTRO, FASCO, Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs, University of Michigan, Ann Arbor, underscored the remarkable potential of short-course radiation to transform the...

breast cancer

Hypofractionation Shows Comparable Results to Conventional Postmastectomy Radiation Therapy, With Added Benefits

In a major development in the treatment of breast cancer, short-course, or hypofractionated, radiation therapy has demonstrated comparable outcomes to conventional postmastectomy radiation therapy while reducing treatment breaks and financial toxicity, according to data presented at the 2023...

Expert Point of View: Bonnie Ky, MD, MSCE, FACC

Bonnie Ky, MD, MSCE, FACC, underscored the significant disparities in cardiovascular risk factors by race and ethnicity among adult survivors of childhood cancer, noting the increased risk of hypertension, diabetes, and obesity among non-Hispanic Black and Hispanic cancer survivors compared with...

survivorship

Survivors of Childhood Cancer: Study Shows Heart-Related Ailments Linked to Radiotherapy Dose

Research on the advances in radiation modeling presented by Rebecca M. Howell, PhD, at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting may provide insights into the late cardiac effects of survivors of childhood cancer in the Childhood Cancer Survivor Study (CCSS).1 Dr....

Expert Point of View: Beth Beadle, MD, PhD

Abstract discussant Beth Beadle, MD, PhD, Professor and Director of Head and Neck Radiation Oncology at Stanford University, underscored the significance of the HYPNO trial in advancing global cancer care, especially in underprivileged settings. “This trial could lead to a crucial change in...

global cancer care

Short-Course Radiotherapy May Reduce Resource Burden of Head and Neck Cancer Treatment in Low- and Middle-Income Countries

Resource-sparing hypofractionated radiation therapy could offer an invaluable alternative for treating head and neck cancer, especially for patients in low- and middle-income countries, according to data presented during the Plenary Session at the 2023 American Society for Radiation Oncology...

gastroesophageal cancer
gastrointestinal cancer

Novel Antibody-Drug Conjugate Shows Potential in Treating CLDN18.2-Positive Gastric and GEJ Cancers

A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may be a new treatment option for patients with advanced gastric/gastroesophageal junction (GEJ) cancers, according to data presented by Xu et al during the ASCO Plenary Series: November 2023 Session (Abstract 434420)....

Expert Point of View: Rohann J.M. Correa, MD, PhD

Abstract discussant Rohann J.M. Correa, MD, PhD, a radiation oncologist at London Health Sciences Centre and Assistant Professor at Western University, Canada, shared his insights on this landmark clinical trial for the treatment of kidney cancers. “FASTRACK II represents an important milestone,...

kidney cancer

Stereotactic Body Radiation Therapy Demonstrates ‘Exceptional Control’ in Primary Renal Cell Carcinoma

Although surgery remains the standard of care for primary renal cell carcinoma, a novel, noninvasive approach has yielded positive results that could pave the way for future treatment strategies, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual...

Expert Point of View: Neha Vapiwala, MD, FASTRO

Discussant of the PACE-B abstract, Neha Vapiwala, MD, FASTRO, acknowledged the impressive efforts of PACE investigators to elucidate the various treatment options for patients with localized prostate cancer—a challenging task because of the frequent absence of clear evidence. Dr. Vapiwala is...

prostate cancer

PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer

Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...

lung cancer

Combination of Ceralasertib and Durvalumab Shows Activity in Phase II Trial of Advanced NSCLC

The combination of the ATR inhibitor ceralasertib and the immune checkpoint inhibitor durvalumab has demonstrated notable survival rates and clinical benefits among patients who have advanced non–small cell lung cancer (NSCLC) with RAS mutations, according to data presented at the International...

Expert Point of View: Martina C. Murphy, MD

Discussant of the ENGOT-EN5/GOG-305/SIENDO trial, Martina C. Murphy, MD, Associate Professor of the Department of Medicine, Division of Hematology, University of Florida, shared insights on the topic of maintenance therapy, its effects on quality of life, and toxicity management. Dr. Murphy...

Advertisement

Advertisement




Advertisement